SCHEMBL6929804

SCHEMBL6929804

CCOC(=O)c1c[nH]c(C)c1-c1cccc2ccccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 2/20 0.54
CLEC4M Q9H2X3 1/20 0.51
CDC25A P30304 1/20 0.51
CDC25C P30307 1/20 0.51
FNTA P49354 1/20 0.50
FNTB P49356 1/20 0.50
TSHR P16473 1/20 0.46
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 3/20 0.45
KMT2A Q03164 4/20 0.45
MEN1 O00255 3/20 0.45
MAPT P10636 2/20 0.45
USP2 O75604 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C9 P11712 1/20 0.45
ALOX15 P16050 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPK10 P53779 1/20 0.45
PTK2B Q14289 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2129231 0.84 CDC25B (0.62) CDC25BCDC25ACDC25CFNTAFNTB
SCHEMBL28004714 0.82 CDC25B (0.61) CDC25BCDC25ACDC25CFNTAFNTB
SCHEMBL6922777 0.82 KDM4E (0.52) CDC25BKDM4EALDH1A1KMT2AMEN1
SCHEMBL6598620 0.80 CDC25B (0.58) CDC25BCLEC4MCDC25ACDC25CFNTA
SCHEMBL4072424 0.79 CDC25B (0.68) CDC25BCLEC4MCDC25ACDC25CFNTA
SCHEMBL2129233 0.79 CDC25B (0.57) CDC25BCDC25ACDC25CFNTAFNTB
SCHEMBL291900 0.78 CDC25B (0.62) CDC25BCDC25ACDC25CFNTAFNTB
SCHEMBL18428555 0.78 CDC25B (0.67) CDC25BCLEC4MCDC25ACDC25CFNTA
SCHEMBL28726472 0.78 CDC25B (0.59) CDC25BCDC25ACDC25CFNTAFNTB
SCHEMBL860937 0.77 TYMS (0.50) TSHRKDM4EALDH1A1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1188407-C Imidazole derivatives with inhabiting activity to transterasa and preparing method thereof LG CHEMICAL LTD (KR) 2005-02-09 CN disclosed
EP-1045846-B1 IMIDAZOLE DERIVATIVES HAVING AN INHIBITORY ACTIVITY FOR FARNESYL TRANSFERASE AND PROCESS FOR PREPARATION THEREOF LG CHEMICAL LTD (KR) 2003-05-02 EP disclosed
US-6518429-B2 Anticancer agents, treating restenosis, atherosclerosis and hepatitis virus LG CHEMICAL, LTD. (KR) 2003-02-11 US disclosed
US-6472526-B1 SHOWS AN INHIBITORY ACTIVITY AGAINST FARNESYL TRANSFERASE OR PHARMACEUTICALLY ACCEPTABLE SALTS OR ISOMERS THEREOF, IN PHARMACEUTICAL COMPOSITION AND INTERMEDIATES LG CHEMICAL LTD. (KR) 2002-10-29 US disclosed
US-20020137769-A1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof LG CHEMICAL LTD. 2002-09-26 US disclosed
US-6268363-B1 ANTITUMOR LG CHEMICAL LTD. (KR) 2001-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020137769-A1 Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof FNTA, FNTB, FDPS CDC25B 774/4885CLEC4M 3282/4885CDC25A 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.